Catalyst Pharmaceutical Partners to Present at 25th Annual ROTH Conference

Thu Mar 7, 2013 8:03am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130307:nGNXUXHVNa

CORAL GABLES, Fla., March 7, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc.
(Nasdaq:CPRX) announced today that Patrick J. McEnany, Catalyst's Chief Executive Officer, and
Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will be presenting an overview of
the company and its progress in key programs at the 25th Annual ROTH Conference, which is being
held on March 17-20, 2013 at the Ritz-Carlton in Dana Point, CA.

The presentation will occur on Tuesday, March 19th at 10:00am PT / 1:00pm ET and will be posted at
http://ir.catalystpharma.com/events.cfm
http://www.globenewswire.com/newsroom/ctr?d=10024314&l=2&u=http%3A%2F%2Fir.catalystpharma.com%2Fevents.cfm
.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neurological
diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and
Tourette's syndrome. Catalyst's lead candidate, Firdapse for the treatment of LEMS, is currently
undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing
a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat
infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement
disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. A number of factors, including whether any
of the Company's product candidates will ever be approved for commercialization and those factors
described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect the Company. Copies of the Company's filings with the SEC are available from the
SEC, may be found on the Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained herein, which speaks
only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
         
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.